ACCP Evidence-Based Clinical Practice Guidelines

2004;126;35-62 Chest Douglas C. McCrory, Gerald Simonneau and Vallerie V. McLaughlin David B. Badesch, Steve H. Abman, Gregory S. Ahearn, Robyn J. Barst, Clinical Practice Guidelines Hypertension: ACCP Evidence-Based Medical Therapy For Pulmonary Arterial http://chestjournal.org/cgi/content/abstract/126/1_suppl/35S and services can be found online on the World Wide Web at: The online version of this article, along with updated information ). ISSN: 0012-3692. http://www.chestjournal.org/misc/reprints.shtml ( of the copyright holder may be reproduced or distributed without the prior written permission Northbrook IL 60062. All rights reserved. No part of this article or PDF by the American College of Chest Physicians, 3300 Dundee Road, 2007 Physicians. It has been published monthly since 1935. Copyright CHEST is the official journal of the American College of Chest

[1]  S. Braman.  Chronic Cough Due to Acute Bronchitis , 2006, Chest.

[2]  S. Braman.  Chronic Cough Due to Chronic Bronchitis , 2006, Chest.

[3]  M. Rosen.  Chronic cough due to tuberculosis and other infections: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[4]  L. Goldstein,et al.  Cough and aspiration of food and liquids due to oral-pharyngeal dysphagia: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[5]  U. Prakash.  Uncommon causes of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[6]  P. Dicpinigaitis.  Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[7]  F. Mccool,et al.  Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[8]  S. Tarlo.  Cough: occupational and environmental considerations: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[9]  K. Brown.  Chronic cough due to nonbronchiectatic suppurative airway disease (bronchiolitis): ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[10]  R. Irwin.  Assessing cough severity and efficacy of therapy in clinical research: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[11]  L. Boulet,et al.  An empiric integrative approach to the management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[12]  M. Pratter,et al.  Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[13]  C. Brightling.  Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[14]  P. Kvale.  Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[15]  M. Pratter.  Unexplained (idiopathic) cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[16]  R. Irwin.  Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[17]  R. Irwin.  Complications of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[18]  M. Pratter.  Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[19]  D. Mccrory,et al.  Methodology and grading of the evidence for the diagnosis and management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[20]  D. Bolser.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[21]  P. Dicpinigaitis.  Potential future therapies for the management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[22]  L. Boulet.  Future directions in the clinical management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[23]  S. Tarlo.  Peritoneal dialysis and cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[24]  M. Rosen.  Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[25]  F. Mccool,et al.  Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[26]  P. Dicpinigaitis.  Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[27]  K. Brown.  Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[28]  M. Rosen.  Cough in the immunocompromised host: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[29]  S. Braman.  Postinfectious cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[30]  B. Canning.  Anatomy and neurophysiology of the cough reflex: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[31]  Eric J Carro-Jiménez,et al.  Primary pulmonary hypertension and pregnancy. , 2005, Boletin de la Asociacion Medica de Puerto Rico.

[32]  Chen Wang,et al.  [Surgical treatment of chronic pulmonary thromboembolism]. , 2005, Zhonghua wai ke za zhi [Chinese journal of surgery].

[33]  T. Penzel,et al.  Sleep apnea and pulmonary hypertension , 1986, Klinische Wochenschrift.

[34]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[35]  Ph.D. Dr. Walter J. Paulus M.D..  Endothelial control of vascular and myocardial function in heart failure , 2004, Cardiovascular Drugs and Therapy.

[36]  W. Krause,et al.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man , 2004, European Journal of Clinical Pharmacology.

[37]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[38]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[39]  H. Okumura,et al.  Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. , 2003, Chest.

[40]  W. Seeger,et al.  Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[41]  R. Barst,et al.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[42]  G. Funk,et al.  Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.

[43]  H. Dincer,et al.  Pathophysiology of pulmonary hypertension due to lung disease , 2003, Current opinion in pulmonary medicine.

[44]  M. Ando,et al.  Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. , 2003, Chest.

[45]  S. Rich,et al.  Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.

[46]  R. Hetzer,et al.  Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. , 2003, European heart journal.

[47]  V. Mathew,et al.  The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. , 2003, Indian heart journal.

[48]  A. Branzi,et al.  The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.

[49]  G. Barnes,et al.  Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. , 2002, Journal of pediatric gastroenterology and nutrition.

[50]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[51]  N. Pereira,et al.  Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.

[52]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[53]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[54]  C. Narasimhan,et al.  A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.

[55]  C. Klersy,et al.  Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status , 2002, Thorax.

[56]  S. Rich,et al.  Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.

[57]  T. Shiomi,et al.  Pulmonary hypertension in patients with severe obstructive sleep apnea , 2002, Psychiatry and clinical neurosciences.

[58]  G. Simonneau,et al.  New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[59]  W. Klepetko,et al.  Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[60]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[61]  P. Lavie,et al.  Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. , 2002, American journal of respiratory and critical care medicine.

[62]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[63]  E. Michelakis,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide , 2002, Circulation.

[64]  Crispin Jenkinson,et al.  Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial , 2002, The Lancet.

[65]  G. Verleden,et al.  Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.

[66]  T. Sundt,et al.  Lung transplantation for pulmonary vascular disease. , 2002, The Annals of thoracic surgery.

[67]  Kevin Gleeson,et al.  Obstructive apnea during sleep is associated with peripheral vasoconstriction. , 2002, American journal of respiratory and critical care medicine.

[68]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[69]  M. Alchanatis,et al.  Daytime Pulmonary Hypertension in Patients with Obstructive Sleep Apnea , 2001, Respiration.

[70]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[71]  B. Cairns,et al.  Inhaled Nitric Oxide for Primary Pulmonary Hypertension in Pregnancy , 2001, Obstetrics and gynecology.

[72]  G. Castro.  [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[73]  J. Orens,et al.  Lung transplantation for primary and secondary pulmonary hypertension. , 2001, The Annals of thoracic surgery.

[74]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[75]  G. Sybrecht,et al.  Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[76]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[77]  A. Arroliga,et al.  Nocturnal hypoxemia is common in primary pulmonary hypertension. , 2001, Chest.

[78]  William C. Cockerham.  Physicians , 2001, BMJ : British Medical Journal.

[79]  B. Winters,et al.  Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[80]  L. Monnery,et al.  Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. , 2001, British journal of anaesthesia.

[81]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[82]  F. Narducci,et al.  Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[83]  T. Kuriyama,et al.  The influence of fractional pulse pressure on the outcome of pulmonary thromboendarterectomy. , 2001, The European respiratory journal.

[84]  G. Olson,et al.  Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy. , 2001, Chest.

[85]  M. Uematsu,et al.  Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.

[86]  K. Bremme,et al.  Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.

[87]  A. Loeckinger,et al.  Sildenafil modulates hemodynamics and pulmonary gas exchange. , 2001, American journal of respiratory and critical care medicine.

[88]  J. Feinstein,et al.  Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2001, Circulation.

[89]  W. Seeger,et al.  Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. , 2001, The European respiratory journal.

[90]  C W Whitney,et al.  Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. , 2001, American journal of respiratory and critical care medicine.

[91]  W K Lam,et al.  Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. , 2000, American journal of respiratory and critical care medicine.

[92]  J. Laaban,et al.  Pulmonary arterial hypertension in patients with sleep apnoea syndrome , 2000, Thorax.

[93]  H. Farber,et al.  Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.

[94]  I. Khan,et al.  HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.

[95]  P. Kuo,et al.  Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. , 2000, Transplantation.

[96]  W. Hurford,et al.  Effects of Intravenous Zaprinast and Inhaled Nitric Oxide on Pulmonary Hemodynamics and Gas Exchange in an Ovine Model of Acute Respiratory Distress Syndrome , 2000, Anesthesiology.

[97]  W. Vogel,et al.  Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. , 2000, Wiener klinische Wochenschrift.

[98]  B. Besse,et al.  Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. , 2000, Circulation.

[99]  K. Kerr,et al.  The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. , 2000, American journal of respiratory and critical care medicine.

[100]  M. Hoeper,et al.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.

[101]  C. Pedersen,et al.  Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. , 2000, The European respiratory journal.

[102]  W. Seeger,et al.  Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.

[103]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[104]  F. Grover,et al.  Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. , 2000, The Journal of thoracic and cardiovascular surgery.

[105]  G. Snell,et al.  Bilateral sequential single lung transplantation for pulmonary hypertension and Eisenmenger's syndrome. , 2000, The Annals of thoracic surgery.

[106]  R. Aubry,et al.  Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report. , 2000, The Journal of reproductive medicine.

[107]  A. Haverich,et al.  Ten years experience with lung and heart-lung transplantation in primary and secondary pulmonary hypertension. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[108]  Inda,et al.  A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .

[109]  W. Seeger,et al.  A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[110]  Erry,et al.  Prospective study of the association between sleep-disordered breathing and hypertension. , 2000, The New England journal of medicine.

[111]  J. Pearl,et al.  Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. , 1999, The Annals of thoracic surgery.

[112]  S. Rich,et al.  The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[113]  M. Vayssairat.  Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. , 1999, The Journal of rheumatology.

[114]  Y. Okano,et al.  Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[115]  R. Wiesner,et al.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.

[116]  A. Atz,et al.  Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. , 1999, Anesthesiology.

[117]  Crispin Jenkinson,et al.  Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial , 1999, The Lancet.

[118]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[119]  A. Chaouat,et al.  Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.

[120]  H. Kimura,et al.  Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. , 1999, American journal of respiratory and critical care medicine.

[121]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[122]  R. Mcevoy,et al.  Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. , 1999, American journal of respiratory and critical care medicine.

[123]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[124]  M. Landzberg,et al.  Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. , 1999, American journal of obstetrics and gynecology.

[125]  R. Whyte,et al.  Heart-lung transplantation for primary pulmonary hypertension. , 1999, The Annals of thoracic surgery.

[126]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[127]  P. Huang,et al.  The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.

[128]  G. Remuzzi,et al.  Endothelin antagonists , 1999, The Lancet.

[129]  K.,et al.  Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. , 1998, British journal of anaesthesia.

[130]  S. Rybalkin,et al.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[131]  D. Ivy,et al.  Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. , 1998, The Journal of pediatrics.

[132]  L. Boulet,et al.  Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. , 1998, Chest.

[133]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[134]  D. Ivy,et al.  Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, Chest.

[135]  J. W. Miller,et al.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.

[136]  O. Hess,et al.  Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.

[137]  W R Clarke,et al.  Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.

[138]  D. Ivy,et al.  Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. , 1998, The Journal of thoracic and cardiovascular surgery.

[139]  M. Maclean.  Endothelin-1: a mediator of pulmonary hypertension? , 1998, Pulmonary pharmacology & therapeutics.

[140]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[141]  C. Howell,et al.  Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.

[142]  R. D. Rudic,et al.  Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. , 1998, The Journal of clinical investigation.

[143]  B. Griffith,et al.  Single- versus double-lung transplantation for pulmonary hypertension. , 1998, The Journal of thoracic and cardiovascular surgery.

[144]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[145]  E. Block,et al.  A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.

[146]  B. Sanner,et al.  Pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1997, Archives of internal medicine.

[147]  G. Dekan,et al.  Bilateral lung transplantation for pulmonary hypertension. , 1997, Transplantation proceedings.

[148]  N. Hill,et al.  Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. , 1997, Journal of applied physiology.

[149]  T. Kuriyama,et al.  The efficacy of pulmonary thromboendarterectomy on long-term gas exchange. , 1997, The European respiratory journal.

[150]  B. Brundage,et al.  Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.

[151]  K. Maruyama,et al.  Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. , 1997, Circulation.

[152]  R. Dixon,et al.  Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. , 1997, Journal of Medicinal Chemistry.

[153]  Y. Okano,et al.  Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.

[154]  A. Halbower,et al.  Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. , 1997, The American journal of physiology.

[155]  B. Griffith,et al.  Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[156]  J P Cooke,et al.  Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.

[157]  R. Speich,et al.  HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.

[158]  B. Clark,et al.  Outcome of children with pulmonary hypertension referred for lung or heart and lung transplantation. , 1996, Transplantation.

[159]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[160]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[161]  T. Saji,et al.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.

[162]  W. Auger,et al.  Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.

[163]  D. Schraufnagel,et al.  Structural and pathologic changes in the lung vasculature in chronic liver disease. , 1996, Clinics in chest medicine.

[164]  L. Sharples,et al.  Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors. , 1996, Transplantation.

[165]  A. Chaouat,et al.  Pulmonary Hemodynamics in the Obstructive Sleep Apnea Syndrome: Results in 220 Consecutive Patients , 1996 .

[166]  P. Ganz,et al.  Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.

[167]  S. Okazaki,et al.  Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. , 1996, General pharmacology.

[168]  S. Nishio,et al.  Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.

[169]  K. Morris,et al.  Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.

[170]  S. Oparil,et al.  Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. , 1995, Journal of applied physiology.

[171]  N. Voelkel,et al.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.

[172]  J. Russell,et al.  The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[173]  M. Pasque,et al.  Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. , 1995, Circulation.

[174]  S. Das,et al.  Nitric oxide: its identity and role in blood pressure control. , 1995, Life sciences.

[175]  D. Stewart,et al.  Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.

[176]  R. Cohen,et al.  The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. , 1995, Progress in cardiovascular diseases.

[177]  J. Loscalzo,et al.  Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.

[178]  P. Vanhoutte,et al.  Endothelium-dependent responses in hypertension. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.

[179]  D. Harrison,et al.  Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. , 1995, The Journal of clinical investigation.

[180]  T. Spray,et al.  Lung transplantation in children and young adults with cardiovascular disease. , 1995, The Annals of thoracic surgery.

[181]  A. Quyyumi,et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.

[182]  G. Pieper,et al.  Amelioration by L‐Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic Endothelium , 1995, Journal of cardiovascular pharmacology.

[183]  D. Mitchell,et al.  AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.

[184]  J. Sandoval,et al.  Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.

[185]  A. Denjean,et al.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.

[186]  P. Bruni,et al.  Identification of a specific transport system for L-arginine in human platelets. , 1995, Biochemical and biophysical research communications.

[187]  P. Dartevelle,et al.  Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. , 1995, Chest.

[188]  C. Bose,et al.  Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. , 1995, Biology of the neonate.

[189]  T. Rector,et al.  Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. , 1994, The American journal of cardiology.

[190]  B. Griffith,et al.  Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. , 1994, The Journal of thoracic and cardiovascular surgery.

[191]  B. Griffith,et al.  Impact of pulmonary hypertension on outcome after single-lung transplantation. , 1994, The Annals of thoracic surgery.

[192]  K. Yamane.  Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. , 1994, Internal medicine.

[193]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[194]  R. Cramb,et al.  Pulmonary hypertension and pregnancy: a series of eight cases , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[195]  S. Hohnloser,et al.  Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .

[196]  G. Simonneau,et al.  Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.

[197]  J. Stamler,et al.  Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.

[198]  K. Ivanova,et al.  Soluble Guanylyl Cyclase and Platelet Function a , 1994, Annals of the New York Academy of Sciences.

[199]  W. Clarke,et al.  The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. , 1994, Pulmonary pharmacology.

[200]  D. Hayoz,et al.  Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. , 1994, Arzneimittel-Forschung.

[201]  L. Raij,et al.  Glomerular thrombosis in pregnancy: role of the L-arginine-nitric oxide pathway. , 1994, Kidney international.

[202]  W. Hurford,et al.  Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. , 1994, Chest.

[203]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[204]  G. Patterson,et al.  Results of single and bilateral lung transplantation in 131 consecutive recipients. Washington University Lung Transplant Group. , 1994, The Journal of thoracic and cardiovascular surgery.

[205]  K. Żmudka,et al.  Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. , 1994, Wiener klinische Wochenschrift.

[206]  J. Kellum,et al.  Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. , 1994, Life sciences.

[207]  R. Trifiletti,et al.  Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.

[208]  W. Vogel,et al.  Effects of repeated stress on plasma arginine levels in young and old rats , 1993, Physiology & Behavior.

[209]  D. Hayoz,et al.  Endothelial function in congestive heart failure. , 1993, American heart journal.

[210]  P. Macchiarini,et al.  Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. , 1993, The Journal of thoracic and cardiovascular surgery.

[211]  T. Evans,et al.  L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. , 1993, British journal of clinical pharmacology.

[212]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[213]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[214]  T. Young,et al.  The occurrence of sleep-disordered breathing among middle-aged adults. , 1993, The New England journal of medicine.

[215]  T. McMahon,et al.  Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.

[216]  T Takishima,et al.  Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. , 1993, Japanese circulation journal.

[217]  B. Groves,et al.  CORRELATION OF ACUTE PROSTACYCLIN RESPONSE IN PRIMARY (UNEXPLAINED) PULMONARY HYPERTENSION WITH EFFICACY OF TREATMENT WITH CALCIUM CHANNEL BLOCKERS AND SURVIVAL , 1993 .

[218]  T. Gasior,et al.  Pulmonary hypertension and liver transplantation. , 1993, Anesthesiology.

[219]  S. Moncada,et al.  The biological and pharmacological role of nitric oxide in platelet function. , 1993, Advances in experimental medicine and biology.

[220]  T. Lüscher,et al.  Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.

[221]  T. Lüscher,et al.  Endothelial dysfunction in coronary artery disease. , 1993, Annual review of medicine.

[222]  S. Soifer,et al.  M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.

[223]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[224]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[225]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[226]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[227]  S. Rich,et al.  Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. , 1992, Journal of the American College of Cardiology.

[228]  J. Stamler,et al.  Endothelium‐Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine , 1992, Journal of cardiovascular pharmacology.

[229]  E. Bassenge.  Clinical relevance of endothelium-derived relaxing factor (EDRF). , 1992, British journal of clinical pharmacology.

[230]  E. Shaffer,et al.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. , 1992, Lancet.

[231]  T. Lüscher,et al.  Endothelium‐Dependent Regulation of Resistance Arteries: Alterations with Aging and Hypertension , 1992, Journal of cardiovascular pharmacology.

[232]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[233]  T. Higenbottam,et al.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.

[234]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[235]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[236]  M. Kramer,et al.  Clinical significance of hyperbilirubinemia in patients with pulmonary hypertension undergoing heart-lung transplantation. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[237]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[238]  E. Sybertz,et al.  Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. , 1991, Advances in experimental medicine and biology.

[239]  J. Krieger,et al.  Frequency and mechanism of daytime pulmonary hypertension in patients with obstructive sleep apnoea syndrome. , 1991, Cor et Vasa.

[240]  J. Cooke,et al.  L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. , 1990, Circulation research.

[241]  S. Abman,et al.  Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.

[242]  J. Beavo,et al.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. , 1990, Trends in pharmacological sciences.

[243]  B. Groves,et al.  26. Pulmonary Hypertension Associated with Hepatic Cirrhosis , 1990 .

[244]  J. Rachocka,et al.  [Primary pulmonary hypertension in children]. , 1990, Wiadomosci lekarskie.

[245]  E. Sforza,et al.  Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. , 1989, Chest.

[246]  J. Bultinck,et al.  Pulmonary fat embolism presenting as chronic respiratory failure. , 1989, The European respiratory journal.

[247]  J. Krieger,et al.  Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1988, The American review of respiratory disease.

[248]  W. Edwards,et al.  Coexistent pulmonary and portal hypertension: morphologic and clinical features. , 1987, Journal of the American College of Cardiology.

[249]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[250]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[251]  J. Haze,et al.  Obstructive sleep apnea. , 1987, Cranio : the journal of craniomandibular practice.

[252]  W. J. Visek,et al.  Arginine needs, physiological state and usual diets. A reevaluation. , 1986, The Journal of nutrition.

[253]  L. Zieve.  Conditional deficiencies of ornithine or arginine. , 1986, Journal of the American College of Nutrition.

[254]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[255]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[256]  R. San Antonio,et al.  Laennec's cirrhosis and primary pulmonary hypertension. , 1980, American heart journal.

[257]  P. Ogburn,et al.  Levels of free fatty acids and arachidonic acid in pregnancy and labor. , 1980, The Journal of laboratory and clinical medicine.

[258]  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.

[259]  S. Sothy,et al.  Carbohydrate and lipid metabolism during human labor: free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. , 1976, Metabolism: clinical and experimental.

[260]  A. Fishman.  Dietary Pulmonary Hypertension , 1974, Circulation research.

[261]  G. Kerr.  The Free Amino Acids of Serum During Development of Macaca mulatto II. During Pregnancy and Fetal Life , 1968, Pediatric Research.

[262]  G. H. Nelson,et al.  Alterations of plasma free fatty acids and glucose during labor. , 1967, American journal of obstetrics and gynecology.

[263]  H. Mendelow,et al.  CONCURRENT "ACTIVE JUVENILE CIRRHOSIS" AND "PRIMARY PULMONARY HYPERTENSION". , 1965, The American journal of medicine.

[264]  L. Dunn,et al.  PRIMARY PULMONARY HYPERTENSION IN PREGNANCY. , 1964, Obstetrical & gynecological survey.

[265]  R. Naeye.  "Primary" Pulmonary Hypertension with Coexisting Portal Hypertension: A Retrospective Study of Six Cases , 1960, Circulation.

[266]  E. Craige,et al.  Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. , 1951, A.M.A. archives of pathology.